TABLE 1 .
Summary of cross-reactivity of the human anti-FHbp Fabsa
| Fab no.b | Cross-reactivity result for FHbp with indicated IDc |
|||||||
|---|---|---|---|---|---|---|---|---|
| Variant group 1 |
Variant group 2 |
Variant group 3 | ||||||
| 1 | 4 | 13 | 74 | 55 | 22 | 77 | 28 | |
| 1A | +d | − | − | − | − | − | − | − |
| 2A | + | − | − | − | − | − | − | − |
| 3C | + | − | − | − | − | − | − | − |
| 4B | + | + | − | − | − | − | − | − |
| 5B | + | + | − | − | − | − | − | − |
| 6B | + | + | − | + | − | − | − | − |
| 7B | + | + | + | + | + | − | − | − |
| 8A | + | + | + | + | + | − | − | − |
| 9B | + | + | + | + | + | + | + | + |
| 10C | + | + | + | + | + | + | + | + |
a
Tested by inhibition ELISA using soluble FHbp variants as inhibitors (see Materials and Methods).
b
Suffixes A, B, and C correspond to the three different human subjects.
c
FHbp ID number from the public database at http://pubmlst.org/neisseria/fHbp and variant group number as described by Masignani et al. (8).
d
+, at least 40% inhibition at the highest inhibitor concentration tested (50 µg/ml); −, less than 40% inhibition at the highest inhibitor concentration tested.